The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Michael P. Johnson

Neuroscience Department

Lilly Research Laboratories

Lilly Corporate Center




Name/email consistency: high



  • Neuroscience Department, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, USA. 1999 - 2005
  • Neuroscience Department, Eli Lilly and Company, Indianapolis, IN 46285, USA. 2002
  • Hoechst Marion Roussel, CNS Research, Cincinnati, OH 45215, USA. 1998


  1. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Johnson, M.P., Barda, D., Britton, T.C., Emkey, R., Hornback, W.J., Jagdmann, G.E., McKinzie, D.L., Nisenbaum, E.S., Tizzano, J.P., Schoepp, D.D. Psychopharmacology (Berl.) (2005) [Pubmed]
  2. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. Johnson, M.P., Nisenbaum, E.S., Large, T.H., Emkey, R., Baez, M., Kingston, A.E. Biochem. Soc. Trans. (2004) [Pubmed]
  3. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. Johnson, M.P., Baez, M., Jagdmann, G.E., Britton, T.C., Large, T.H., Callagaro, D.O., Tizzano, J.P., Monn, J.A., Schoepp, D.D. J. Med. Chem. (2003) [Pubmed]
  4. Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268. Johnson, M.P., Chamberlain, M. Neuropharmacology (2002) [Pubmed]
  5. Changes in rat serum corticosterone after treatment with metabotropic glutamate receptor agonists or antagonists. Johnson, M.P., Kelly, G., Chamberlain, M. J. Neuroendocrinol. (2001) [Pubmed]
  6. Blockade of pilocarpine-induced cerebellar phosphoinositide hydrolysis with metabotropic glutamate antagonists: evidence for an indirect control of granule cell glutamate release by muscarinic agonists. Johnson, M.P., Kelly, G.M., Chamberlain, M. Neurosci. Lett. (2000) [Pubmed]
  7. Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists. Johnson, M.P., Chamberlain, M., Kelly, G.M. Brain Res. (1999) [Pubmed]
  8. Temporal dependent neuroprotection with propentofylline (HWA 285) in a temporary focal ischemia model. Johnson, M.P., McCarty, D.R., Chmielewski, P.A. Eur. J. Pharmacol. (1998) [Pubmed]
  9. MDL 101,002, a free radical spin trap, is efficacious in permanent and transient focal ischemia models. Johnson, M.P., McCarty, D.R., Velayo, N.L., Markgraf, C.G., Chmielewski, P.A., Ficorilli, J.V., Cheng, H.C., Thomas, C.E. Life Sci. (1998) [Pubmed]
WikiGenes - Universities